Xenon Pharmaceuticals Inc. Aktie News

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) announced its latest new order for a Xenon MRI System, from the University of Alabama at Birmingham (UAB) Hospital. The order from the hospital, a top-tier academic institution in the southeastern United States, extends the company's innovative imaging technology to an additional major hospital for the first time, Polarean noted.

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a leader in advanced MRI technology, has been selected as a featured company and poster presenter at the upcoming American Thoracic Society's 2024 Respiratory Innovation Summit. A key gathering for those involved in pulmonary medicine, the event, which takes place from May 17-18 in San Diego, brings together over 275 global leaders from various sector...

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024.

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.